-

07:50:36 AM

Latest AIM Stock Market News

AIM - AIM ImmunoTech Inc

09/21/21 7:25 AM

AMEX : AIM

clinical trialcovid-19

AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company’s meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion therapy for Post-COVID-19

RHEA-AI

neutral

09/20/21 9:15 AM

AMEX : AIM

clinical trial

AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen

AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company’s drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (HRV-16, a common cold

RHEA-AI

neutral

09/08/21 9:00 AM

AMEX : AIM

clinical trialcovid-19

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potential infusion

RHEA-AI

negative

08/25/21 9:00 AM

AMEX : AIM

covid-19

AIM ImmunoTech Announces Filing of Provisional Patent Application for Use of Ampligen as Both an Intranasal and an IV Therapy for Post-COVID-19 Cognitive Dysfunction (PCCD)

AIM ImmunoTech Inc. (NYSE American: AIM) today provided an update on the company’s

RHEA-AI

neutral

08/17/21 9:00 AM

AMEX : AIM

AIM ImmunoTech Provides Second Quarter 2021 Business Update

AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update. Second Quarter 2021 Financial Highlights: As of June 30, 2021, AIM had cash, cash equivalents and

RHEA-AI

neutral

08/16/21 7:25 AM

AMEX : AIM

management

AIM CEO Thomas K. Equels Named to Board of Directors of BioFlorida Inc.

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that CEO Thomas K. Equels has been appointed to the Board of Directors of BioFlorida Inc., the state’s life sciences

RHEA-AI

neutral

07/09/21 7:25 AM

AMEX : AIM

clinical trial

AIM ImmunoTech Announces Phase 2a Human Challenge Trial to Test its Drug Ampligen as an Intranasal Antiviral Prophylactic Therapy

AIM ImmunoTech Inc. (NYSE

RHEA-AI

neutral

07/06/21 2:15 PM

AMEX : AIM

conferences

AIM ImmunoTech to Host Investor Update Webcast on Wednesday, July 14th at 11:00 AM ET

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it will host an investor update webcast at 11:00 a.m. Eastern Time on Wednesday, July 14, 2021, to discuss recent accomplishments and upcoming milestones. Investors and other interested

RHEA-AI

neutral

06/21/21 9:00 AM

AMEX : AIM

clinical trial

AIM ImmunoTech Completes All Treatments in Phase 1 Human Safety Study of Intranasal Administration of Ampligen

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that all subjects have completed treatment in the Company’s Phase 1 clinical study to assess

RHEA-AI

neutral

06/14/21 7:15 AM

AMEX : AIM

AIM ImmunoTech’s Ampligen Featured in Peer-Reviewed Journal Cancers as a Potential Therapy for Cancer Patients with SARS-CoV-2

AIM ImmunoTech Inc. (NYSE American: AIM) today announced that its drug Ampligen has been featured in a publication

RHEA-AI

very positive